PL2831079T3 - Dwucykliczne heterocykliczne pochodne jako modulatory mnk1 i mnk2 oraz ich zastosowanie - Google Patents

Dwucykliczne heterocykliczne pochodne jako modulatory mnk1 i mnk2 oraz ich zastosowanie

Info

Publication number
PL2831079T3
PL2831079T3 PL13768800T PL13768800T PL2831079T3 PL 2831079 T3 PL2831079 T3 PL 2831079T3 PL 13768800 T PL13768800 T PL 13768800T PL 13768800 T PL13768800 T PL 13768800T PL 2831079 T3 PL2831079 T3 PL 2831079T3
Authority
PL
Poland
Prior art keywords
mnk2
mnk1
modulators
bicyclic heterocyclic
heterocyclic derivatives
Prior art date
Application number
PL13768800T
Other languages
English (en)
Inventor
Kassoum Nacro
Athisayamani Jeyaraj Duraiswamy
Lohitha Rao Chennamaneni
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of PL2831079T3 publication Critical patent/PL2831079T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL13768800T 2012-03-30 2013-04-01 Dwucykliczne heterocykliczne pochodne jako modulatory mnk1 i mnk2 oraz ich zastosowanie PL2831079T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1205669.3A GB201205669D0 (en) 2012-03-30 2012-03-30 Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
EP13768800.8A EP2831079B1 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
PCT/SG2013/000126 WO2013147711A1 (en) 2012-03-30 2013-04-01 Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof

Publications (1)

Publication Number Publication Date
PL2831079T3 true PL2831079T3 (pl) 2018-01-31

Family

ID=46160013

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17179630.3T PL3321268T3 (pl) 2012-03-30 2013-04-01 Bicykliczne pochodne heteroarylowe jako modulatory mnk1 oraz mnk2 i ich zastosowania
PL13768800T PL2831079T3 (pl) 2012-03-30 2013-04-01 Dwucykliczne heterocykliczne pochodne jako modulatory mnk1 i mnk2 oraz ich zastosowanie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17179630.3T PL3321268T3 (pl) 2012-03-30 2013-04-01 Bicykliczne pochodne heteroarylowe jako modulatory mnk1 oraz mnk2 i ich zastosowania

Country Status (14)

Country Link
US (3) US9908886B2 (pl)
EP (2) EP2831079B1 (pl)
JP (2) JP6475158B2 (pl)
KR (1) KR102153320B1 (pl)
CN (1) CN104350055B (pl)
AU (2) AU2013240612B2 (pl)
BR (1) BR112014024255B1 (pl)
DK (1) DK2831079T3 (pl)
ES (2) ES3034431T3 (pl)
GB (1) GB201205669D0 (pl)
NO (1) NO2831079T3 (pl)
PL (2) PL3321268T3 (pl)
SG (2) SG10201706594PA (pl)
WO (1) WO2013147711A1 (pl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TWI574962B (zh) 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
KR102148681B1 (ko) 2013-02-21 2020-08-27 칼리토르 사이언시즈, 엘엘씨 Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
WO2014151729A1 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
GB2518873A (en) * 2013-10-03 2015-04-08 Agency Science Tech & Res Bicyclic alkyne derivatives and uses thereof
CA2930499C (en) * 2013-12-09 2021-11-23 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
MA39186A1 (fr) 2013-12-19 2017-11-30 Novartis Ag Dérivés de [1,2,4]triazolo[1,5-a]pyrimidine utilisés comme inhibiteurs du protéasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose
JP6542236B2 (ja) * 2014-01-09 2019-07-10 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
UA121206C2 (uk) 2014-01-24 2020-04-27 Турнінґ Поінт Терапьютикс, Інк. Діарильні макроцикли як модулятори протеїнкіназ
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
BR112016018555B1 (pt) 2014-02-13 2024-01-23 Incyte Holdings Corporation Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
AU2016252038B2 (en) 2015-04-20 2021-08-12 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
MA41988B1 (fr) * 2015-04-29 2021-03-31 Janssen Pharmaceutica Nv Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
EA201890086A1 (ru) 2015-06-18 2018-06-29 Сефалон, Инк. 1,4-замещенные производные пиперидина
WO2016205590A1 (en) * 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
US10316044B2 (en) 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
HRP20240780T1 (hr) 2015-07-06 2024-09-13 Turning Point Therapeutics, Inc. Polimorf diaril makrocikla
HUE070316T2 (hu) 2015-07-21 2025-05-28 Turning Point Therapeutics Inc Királis diaril makrociklus és annak felhasználása rák kezelésében
CN110402244B (zh) 2015-08-12 2023-02-03 因赛特公司 Lsd1抑制剂的盐
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
KR20180073629A (ko) * 2015-10-22 2018-07-02 셀비타 에스에이 피리돈 유도체 및 키나제 억제제로서의 그의 용도
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
EA034440B1 (ru) * 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
AU2016343687A1 (en) 2015-10-29 2018-06-07 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
WO2017117052A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
US11352328B2 (en) * 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
BR112019001607A2 (pt) 2016-07-28 2019-04-30 Tp Therapeutics, Inc. inibidores macrocíclicos de quinases
GB201700692D0 (en) * 2017-01-16 2017-03-01 Salvensis Novel compounds and their use in the treatment of schistosomiasis
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
AU2018220840A1 (en) 2017-02-14 2019-09-19 Effector Therapeutics, Inc. Piperidine-substituted Mnk inhibitors and methods related thereto
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
SI3728271T1 (sl) 2017-12-19 2023-01-31 Turning Point Therapeutics, Inc. Makrociklične spojine za zdravljenje bolezni
CN115448923B (zh) * 2018-02-13 2024-03-22 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
EP3753941B1 (en) * 2018-02-13 2024-05-01 Shanghai Blueray Biopharma Co., Ltd. Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
EP3856186A4 (en) * 2018-09-28 2022-07-06 Arizona Board of Regents on behalf of the University of Arizona SMALL MOLECULE DYRK1/CLK INHIBITORS AND THEIR USES
CN113286592A (zh) 2018-10-24 2021-08-20 效应治疗股份有限公司 Mnk抑制剂的结晶形式
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CN111978325B (zh) * 2019-05-22 2023-11-17 中国药科大学 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用
CN111978317A (zh) * 2019-05-22 2020-11-24 上海道熵生物科技有限公司 咪唑并吡啶类mnk1/mnk2激酶抑制剂及其制备方法和应用
TWI759829B (zh) 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
CA3148490C (en) 2019-08-30 2024-04-30 Jae Won Lee Imidazopyridine derivative and pharmaceutical composition comprising same as active ingredient
ES3001441T3 (en) * 2019-12-30 2025-03-05 Devicare S L Compositions for clinical complications associated to devices implanted in the urinary tract
CN116194112A (zh) * 2020-06-30 2023-05-30 4E治疗公司 表现出mnk抑制作用的吡啶-1,5-二酮及其使用方法
CN112047950B (zh) * 2020-09-14 2023-07-25 华东师范大学 咪唑并吡嗪类衍生物及其合成方法和应用
EP4210697A1 (en) * 2020-09-14 2023-07-19 The University of Sussex Small molecule inhibitors of lemur tyrosine kinase 3
US20230000986A1 (en) * 2021-07-01 2023-01-05 Board Of Regents, The University Of Texas System Mnk inhibitors and eif4e phosphorylation modulation to treat inflammatory pain in the aged
JP7814782B2 (ja) * 2021-11-29 2026-02-17 オーシャン ユニバーシティ オブ チャイナ イミダゾチアゾール誘導体およびその製造方法と使用
CN114113639B (zh) * 2022-01-29 2022-04-19 北京大有天弘科技有限公司 一种血型抗体检测方法及其应用
CN118908959B (zh) * 2023-05-08 2025-11-14 广西大学 咪唑并[1,2-b]哒嗪类化合物及其制备方法和PI3K抑制剂应用
ES2993583B2 (es) * 2023-06-27 2025-09-22 Univ Valencia Derivados de imidazo[1,2-a]piridina con actividad antiinflamatoria
WO2025165301A1 (en) * 2024-01-31 2025-08-07 National University Of Singapore Targeting metabolic pathways with mnk inhibitors
WO2025247379A1 (zh) * 2024-05-30 2025-12-04 深圳微芯生物科技股份有限公司 一种苯并咪唑类化合物、其制备方法及应用
CN119614691B (zh) * 2024-12-09 2026-03-13 武汉大学 干扰nlk基因靶点在制备改善巨噬细胞炎性激活的药物中的应用
CN121085942A (zh) * 2025-08-28 2025-12-09 中国海洋大学 3，5-位取代的咪唑并噻二唑杂环衍生物及其制备方法与应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
EP1910369A1 (en) * 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US20070049591A1 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7951803B2 (en) * 2006-03-09 2011-05-31 Pharmacopeia, Llc 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders
EP2044051B1 (en) * 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
US20120058997A1 (en) * 2006-11-06 2012-03-08 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
MX2009004700A (es) * 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
US8895745B2 (en) * 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
CN101827844B (zh) * 2007-10-17 2013-08-14 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物
WO2010055072A2 (en) * 2008-11-12 2010-05-20 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating a mnk
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
NZ620020A (en) * 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
JPWO2011136264A1 (ja) * 2010-04-28 2013-07-22 第一三共株式会社 ［５，６］複素環化合物
CA2806655A1 (en) * 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
US10280168B2 (en) 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
JP2016510764A (ja) * 2013-03-07 2016-04-11 カリフィア バイオ, インク.Califia Bio, Inc. 混合系キナーゼ阻害剤および治療法

Also Published As

Publication number Publication date
SG11201406207PA (en) 2014-11-27
ES2647959T3 (es) 2017-12-27
PL3321268T3 (pl) 2025-11-17
GB201205669D0 (en) 2012-05-16
US20140371199A1 (en) 2014-12-18
ES3034431T3 (en) 2025-08-18
US20180208600A1 (en) 2018-07-26
JP2019031560A (ja) 2019-02-28
JP6662984B2 (ja) 2020-03-11
US20190315755A1 (en) 2019-10-17
JP2015511638A (ja) 2015-04-20
DK2831079T3 (da) 2017-11-27
EP2831079A4 (en) 2015-11-18
EP3321268A1 (en) 2018-05-16
BR112014024255B1 (pt) 2021-12-28
KR20150002639A (ko) 2015-01-07
AU2013240612B2 (en) 2017-05-25
EP3321268C0 (en) 2025-06-04
CN104350055B (zh) 2019-05-31
WO2013147711A1 (en) 2013-10-03
AU2013240612A1 (en) 2014-10-16
US11040978B2 (en) 2021-06-22
SG10201706594PA (en) 2017-09-28
EP2831079B1 (en) 2017-08-16
EP2831079A1 (en) 2015-02-04
JP6475158B2 (ja) 2019-02-27
NO2831079T3 (pl) 2018-01-13
EP3321268B1 (en) 2025-06-04
CN104350055A (zh) 2015-02-11
KR102153320B1 (ko) 2020-09-08
BR112014024255A2 (pt) 2017-06-20
US9908886B2 (en) 2018-03-06
AU2017219039A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
SG10201706594PA (en) Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof
IL237126A (en) Derivatives in cicadas
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
SG11201400484RA (en) Novel heterocyclic derivatives and their uses
IL237176A0 (en) Anticholinergic preparation that protects the nervous system and methods
ZA201405253B (en) Heterocyclic compounds and methods for their use
SG11201503535PA (en) Hollow hydrogel capsules and methods of using the same
ZA201405257B (en) Heterocyclic compounds and methods for their use
ZA201405255B (en) Heterocyclic compounds and methods for their use
AP3611A (en) Heterocyclic compounds and their uses
SG11201405036SA (en) Absorber and absorbent article using the same
IL252033B (en) History of spiro and processes for their preparation
SG11201404277WA (en) Aurora and flt3 kinases modulators
GB2500340B (en) Carrying aid especially for use with children
EP2870133A4 (en) TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF
GB201212570D0 (en) Carrying aid especially for use with children
AU2012900986A0 (en) Compounds and Methods - II